此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Validation of the CIDI 5.0 Against the SCID-5 for Lifetime Mental Disorders

2026年5月19日 更新者:Michael Y. Ni、The University of Hong Kong

Validity of the World Health Organization CIDI 5.0 for Assessing Lifetime Prevalence of Mental Disorders: A Clinical Reappraisal Study Using the SCID-5

The World Health Organization Composite International Diagnostic Interview (CIDI) is a fully structured diagnostic tool designed for lay interviewers to assess the prevalence of mental and substance use disorders. Earlier versions, such as the CIDI 3.0, demonstrated acceptable individual-level concordance with clinical assessments based on DSM-IV criteria (Haro et al. 2006). The latest iteration (CIDI 5.0) has been updated to operationalize DSM-5 criteria.

Recent evidence from a large-scale, community-based national study in Qatar suggests that under DSM-5 criteria (Khaled et al. 2024), after recalibration, the CIDI 5.0 maintains high specificity (91.9% for MDD, 94.7% for GAD, and 85.5% for PTSD). Sensitivity suggested CIDI diagnoses aligned closely with clinical "gold standard" diagnoses (51.5% for MDD, 50.7% for GAD, and 77.3% for PTSD). Despite the evidence from Qatar, there remains a lack of evidence regarding the validity of the CIDI 5.0 in population-based studies.

Therefore, this study aims to evaluate the diagnostic validity of the CIDI 5.0 for Lifetime MDD, GAD, and PTSD, using the Structured Clinical Interview for DSM-5 (SCID-5) as the definitive clinical gold standard.

研究概览

研究类型

观察性的

注册 (估计的)

300

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

  • 姓名:Yoona Kim, PhD
  • 电话号码:+852 3917 9109
  • 邮箱:yoonak@hku.hk

学习地点

      • Hong Kong、香港
        • 招聘中
        • The University of Hong Kong
        • 接触:
          • Yoona Kim, PhD
          • 电话号码:+852 3917 9109
          • 邮箱:yoonak@hku.hk

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人
  • 年长者

接受健康志愿者

是的

取样方法

非概率样本

研究人群

This study is a sub-study of the District Health Profile (DHP), which is a district-level representative descriptive cross-sectional study. In DHP, 1% of households in selected Hong Kong districts will be randomly selected from the Census and Statistics Department's list of quarters, with stratification based on districts and housing types; all persons aged 18 and above in the recruited households will be included and surveyed. All individuals will complete the survey for the DHP study, including the CIDI-5 section. Based on prior studies (Haro et al., 2006; Khaled et al., 2024), to ensure adequate statistical power and control for Type I error, the clinical validation study will include 300 individuals. 77 participants will serve as controls with no history of mental disorders, and the remaining sample size will consist of participants with at least one lifetime diagnosis of MDD, GAD, or PTSD, as identified by CIDI-5, aiming to reach at least 112 samples for each diagnosis.

描述

Inclusion Criteria:

  • All household members aged 18 years old and over are randomly sampled from the Census and Statistics Department List of Quarters
  • Live in the address sampled from the Census and Statistics Department List of Quarters
  • Reside in Hong Kong for at least six months in the past year
  • Able to read and communicate in Chinese or English
  • Without linguistic or cognitive difficulties

Exclusion Criteria:

  • Domestic workers

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

队列和干预

团体/队列
干预/治疗
CIDI-5 Validation Cohort
This group consists of participants from the general population who will complete the CIDI-5 interview. A stratified subsample will be selected for a follow-up clinical reappraisal using the SCID-5 to determine diagnostic accuracy.
The World Health Organization Composite International Diagnostic Interview-5th (CIDI-5) is a standardized diagnostic tool used to assess the prevalence of mental and substance use disorders over varying time frames (30 days, 12 months, and lifetime) based on the diagnostic criteria outlined in the Diagnostic and Statistical Manual of Mental Disorders 5th edition (DSM-5) and International Classification of Diseases 10th edition (ICD-10). Trained interviewers will administer selected modules from the Hong Kong version of the CIDI-5 in a computer-assisted personal interview to measure the outcomes. To validate the diagnoses in the CIDI-5 group, investigators will conduct clinical re-interviews of 3 selected CIDI-5 diagnoses: major depressive disorder (MDD), generalized anxiety disorder (GAD), and post-traumatic stress disorder (PTSD) using the Structured Clinician Interview for DSM-5 (SCID) by a trained mental health professional with previous experience using SCID.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
忧虑和焦虑
大体时间:干预或招募后立即
该模块中的主要结果是普遍焦虑症(GAD)的终生患病率
干预或招募后立即
Depression
大体时间:Immediately following intervention or recruitment
The main outcome in this module is the lifetime prevalence of Major Depressive Disorder (MDD)
Immediately following intervention or recruitment
Stressful Experiences
大体时间:Immediately following intervention or recruitment
The main outcome in this module is the lifetime prevalence of PTSD.
Immediately following intervention or recruitment

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2025年5月14日

初级完成 (估计的)

2028年1月1日

研究完成 (估计的)

2028年1月1日

研究注册日期

首次提交

2026年4月9日

首先提交符合 QC 标准的

2026年5月19日

首次发布 (实际的)

2026年5月22日

研究记录更新

最后更新发布 (实际的)

2026年5月22日

上次提交的符合 QC 标准的更新

2026年5月19日

最后验证

2026年4月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

未定

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅